Inovio Presents Data From Phase 1b Trial With INO-4201 As Ebola Booster For RVSV-ZEBOV
17/4 14:21
(RTTNews) - Inovio (INO) said that data from a Phase 1b trial evaluating INO-4201 as an Ebola booster vaccine candidate for rVSV-ZEBOV (Ervebo) (NCT04906629) was presented at the 33rd European Congress of Clinical Microbiology and Infectious Diseases....